Skip to main navigation
Alpine Immune Sciences Alpine Immune Sciences

Main navigation

  • About Us
    • At a Glance
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Partners
    • Contact Us
  • Pipeline & Programs
    • Pipeline
    • ALPN-101
    • ALPN-202
    • ALPN-303
    • Science & Platform
    • Scientific Publications
  • Clinical Trials
  • Investors
    • Stock Information
    • Analyst Coverage
    • News Release
    • Events & Presentations
    • SEC Filings
    • Governance
    • FAQs
    • Investors Contact
  • Careers
  • No menu assigned!

News Releases

Investor Relations - Horizontal

news releases  |  events  |  sec filings  |  governance  | 

board of directors  |  leadership  |  documents  |  committee composition  | 

faqs  |  investors contact  | 
  • December 9, 2019
    Summary ToggleAlpine Immune Sciences Presents ALPN-101 Phase 1 Healthy Volunteer Study Data and Details of Upcoming Phase I/II BALANCE GVHD Study at the 61st American Society of Hematology Annual Meeting
    ALPN-101 demonstrates ability to potently inhibit both T and B cell responses in first-in-human study Human experience supports both IV and SQ dosing regimens SEATTLE --(BUSINESS WIRE)--Dec. 9, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused
    Read More
  • November 26, 2019
    Summary ToggleAlpine Immune Sciences to Participate in Fireside Chat at 31st Annual Piper Jaffray Healthcare Conference
    SEATTLE --(BUSINESS WIRE)--Nov. 26, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced participation in an analyst-led fireside chat at
    Read More
  • November 13, 2019
    Summary ToggleAlpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2019 Financial Results
    Company Advancing ALPN-101 into a Phase 1/2 Acute Graft versus Host Disease Study (BALANCE) Phase 1 Study (NEON-1) of Lead Oncology Program ALPN-202 Planned to Commence in Q1 2020 Conference Call Scheduled for 4:30 p.m. ET Today SEATTLE --(BUSINESS WIRE)--Nov.
    Read More
  • November 12, 2019
    Summary ToggleAlpine Immune Sciences Presents New ALPN-101 Preclinical Data at the 2019 American College of Rheumatology (ACR) Annual Meeting
    ALPN-101 is distinct from the other biologic therapies and superior to combination biological blockade Preclinical activity suggests unique effectiveness across a range of rheumatic and other inflammatory diseases SEATTLE --(BUSINESS WIRE)--Nov. 12, 2019-- Alpine Immune Sciences, Inc.
    Read More
  • November 8, 2019
    Summary ToggleAlpine Immune Sciences Presents New Preclinical Data at The Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
      Preclinical data support unique mechanism of action of ALPN-202 as a first in class conditional CD28 Agonist ALPN-202 able to increase CD8+ T-cells in tumors ALPN-202 has potent monotherapy activity and significantly improves upon the activity of multiple anticancer therapies in preclinical
    Read More
  • November 6, 2019
    Summary ToggleAlpine Immune Sciences Announces Oral Presentation of ALPN-101 at the 61st American Society of Hematology Annual Meeting and Exposition
    SEATTLE --(BUSINESS WIRE)--Nov. 6, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced an abstract has been accepted for an oral
    Read More
  • October 30, 2019
    Summary ToggleAlpine Immune Sciences Completes Enrollment of Phase I Study of ALPN-101 and Announces Third Quarter Conference Call
    Company to Discuss Topline Results and Provide Company Update on Third Quarter 2019 Conference Call and Webcast Scheduled for November 13, 2019 at 4:30 p.m. ET SEATTLE --(BUSINESS WIRE)--Oct. 30, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a clinical-stage immunotherapy company focused on
    Read More
  • October 2, 2019
    Summary ToggleAlpine Immune Sciences Announces Upcoming Scientific Presentations at SITC and ACR/ARHP 2019 Annual Meetings
      SEATTLE --(BUSINESS WIRE)--Oct. 2, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced planned poster presentations at upcoming
    Read More
  • September 17, 2019
    Summary ToggleAlpine Immune Sciences to Present at 2019 Ladenburg Thalmann Healthcare Conference
    SEATTLE --(BUSINESS WIRE)--Sep. 17, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will present at the 2019 Ladenburg
    Read More
  • August 13, 2019
    Summary ToggleAlpine Immune Sciences Provides Pipeline Update and Reports Second Quarter 2019 Financial Results
    ALPN-101 Progresses to Multiple-Ascending Dose Cohorts of Phase I Study ALPN-202 Submission for Clinical Trial Authorization Anticipated by Year End 2019 SEATTLE --(BUSINESS WIRE)--Aug. 13, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on
    Read More

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 3
  • Current page 4
  • Page 5
  • Page 6
  • …
  • Next page Next
  • Last page Last
Displaying 31 - 40 of 98 results

Toolkit

  • Contact Us
  • Email Alerts
  • RSS Feeds
  • Print Page
  • Email Page

Contact

188 East Blaine Street
Suite 200
Seattle, WA
98102
206-788-4545

Sitemap

  • About Us
  • Pipelines & Programs
  • Clinical Trials
  • Investors
  • Careers
  • Contact Us
  • Legal

Twitter

@AlpineImmuneSci

LATEST TWEETS

Tweets by @AlpineImmuneSci

© 2021 Alpine Immune Sciences. All Rights Reserved, Alpine Immune Sciences Inc.

Investor Relations - Horizontal

  • News Releases
  • Events
  • SEC Filings
  • Governance
    • Board of Directors
    • Leadership
    • Documents
    • Committee Composition
  • FAQs
  • Investors Contact